Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumour burden and efficacy of immune-checkpoint inhibitors.
Dall'Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, Besse B. Dall'Olio FG, et al. Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12. Nat Rev Clin Oncol. 2022. PMID: 34642484 Review.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Dall'Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, Fontana F, Terracciano M, Fragomeno B, Tober N, Manferrari G, Brocchi S, Golfieri R, Fiorentino M, Ardizzoni A. Dall'Olio FG, et al. Clin Lung Cancer. 2021 Sep;22(5):423-431. doi: 10.1016/j.cllc.2021.03.005. Epub 2021 Mar 16. Clin Lung Cancer. 2021. PMID: 33849808
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A. Dall'Olio FG, et al. Eur J Cancer. 2021 Jun;150:99-107. doi: 10.1016/j.ejca.2021.03.020. Epub 2021 Apr 20. Eur J Cancer. 2021. PMID: 33892411
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Ann Oncol. 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. Epub 2021 Aug 13. Ann Oncol. 2021. PMID: 34400292 Free article.
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
Cortellini A, Ricciuti B, Vaz VR, Soldato D, Alessi JV, Dall'Olio FG, Banna GL, Muthuramalingam S, Chan S, Majem M, Piedra A, Lamberti G, Andrini E, Addeo A, Friedlaender A, Facchinetti F, Gorría T, Mezquita L, Hoton D, Valerie L, Nana FA, Artingstall J, Comins C, Di Maio M, Caglio A, Cave J, McKenzie H, Newsom-Davis T, Evans JS, Tiseo M, D'Alessio A, Fulgenzi CAM, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: dall olio fg. J Immunother Cancer. 2022 Feb;10(2):e004374. doi: 10.1136/jitc-2021-004374. J Immunother Cancer. 2022. PMID: 35173031 Free PMC article.
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.
Dall'Olio FG, Parisi C, Marcolin L, Brocchi S, Caramella C, Conci N, Carpani G, Gelsomino F, Ardizzoni S, Marchese PV, Paccapelo A, Grilli G, Golfieri R, Besse B, Ardizzoni A. Dall'Olio FG, et al. Ther Adv Med Oncol. 2022 Feb 12;14:17588359211058391. doi: 10.1177/17588359211058391. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173818 Free PMC article.
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.
Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy F, Souquet PJ, Cloarec N, Giroux-Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, Besse B. Barlesi F, et al. Among authors: dall olio fg. Clin Cancer Res. 2022 Sep 15;28(18):4018-4026. doi: 10.1158/1078-0432.CCR-22-0371. Clin Cancer Res. 2022. PMID: 35802649 Clinical Trial.
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
Aldea M, Marinello A, Duruisseaux M, Zrafi W, Conci N, Massa G, Metro G, Monnet I, Gomez Iranzo P, Tabbo F, Bria E, Guisier F, Vasseur D, Lindsay CR, Ponce-Aix S, Cousin S, Citarella F, Fallet V, Minatta JN, Eisert A, de Saint Basile H, Audigier-Valette C, Mezquita L, Calles A, Mountzios G, Tagliamento M, Remon Masip J, Raimbourg J, Terrisse S, Russo A, Cortinovis D, Rochigneux P, Pinato DJ, Cortellini A, Leonce C, Gazzah A, Ghigna MR, Ferrara R, Dall'Olio FG, Passiglia F, Ludovini V, Barlesi F, Felip E, Planchard D, Besse B. Aldea M, et al. Among authors: dall olio fg. J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13. J Thorac Oncol. 2023. PMID: 36646211 Free article.
39 results